The Experts below are selected from a list of 6 Experts worldwide ranked by ideXlab platform

Kaur D - One of the best experts on this subject based on the ideXlab platform.

  • Study on hepatotoxicity and other side-effects of antituberculosis drugs.
    Journal of the Indian Medical Association, 1990
    Co-Authors: Taneja Dp, Kaur D
    Abstract:

    : A prospective study of different side-effects and toxicity of different antituberculosis drugs was made on 125 cases of pulmonary tuberculosis, divided into 3 groups according to the regime of treatment. Group A consisted of 50 patients, taking streptomycin, Ethambutol and Isoniazid. Group B of 50 patients received streptomycin Plus Ethambutol Plus Isoniazid and rifampicin and 25 patients comprising group C received streptomycin Plus Isoniazid Plus Ethambutol and pyrazinamide. The group B showed hepatotoxicity in 30% cases, out of which clinical jaundice with abnormal liver function tests being 26% and rest 4% cases were of anicteric hepatitis, while group A showed only 6% hepatotoxicity with 4% clinical jaundice and 2% anicteric hepatitis. In group A out of 50 cases only 2 patients complained of colour blindness, which reversed with the stoppage of drugs. In group C out of 25 cases 3 patients had gouty problems and responded with stoppage of drugs. Patients in group A developed jaundice in a mean of 50 days while those in group B developed jaundice in 17 days.

Taneja Dp - One of the best experts on this subject based on the ideXlab platform.

  • Study on hepatotoxicity and other side-effects of antituberculosis drugs.
    Journal of the Indian Medical Association, 1990
    Co-Authors: Taneja Dp, Kaur D
    Abstract:

    : A prospective study of different side-effects and toxicity of different antituberculosis drugs was made on 125 cases of pulmonary tuberculosis, divided into 3 groups according to the regime of treatment. Group A consisted of 50 patients, taking streptomycin, Ethambutol and Isoniazid. Group B of 50 patients received streptomycin Plus Ethambutol Plus Isoniazid and rifampicin and 25 patients comprising group C received streptomycin Plus Isoniazid Plus Ethambutol and pyrazinamide. The group B showed hepatotoxicity in 30% cases, out of which clinical jaundice with abnormal liver function tests being 26% and rest 4% cases were of anicteric hepatitis, while group A showed only 6% hepatotoxicity with 4% clinical jaundice and 2% anicteric hepatitis. In group A out of 50 cases only 2 patients complained of colour blindness, which reversed with the stoppage of drugs. In group C out of 25 cases 3 patients had gouty problems and responded with stoppage of drugs. Patients in group A developed jaundice in a mean of 50 days while those in group B developed jaundice in 17 days.

Claire Andrejak - One of the best experts on this subject based on the ideXlab platform.

  • Treatment of Other Nontuberculous Mycobacteria.
    Seminars in Respiratory and Critical Care Medicine, 2018
    Co-Authors: D. Basille, Vincent Jounieaux, Claire Andrejak
    Abstract:

    Nontuberculous mycobacteria (NTM) are numerous, and for the vast majority of them, randomized studies are lacking and data regarding optimal treatment are limited. When Mycobacterium avium complex (MAC) and M. abscessus are excluded, the main NTM are M. xenopi, M. kansasii, M. malmoense, M. szulgai, and M. simiae. Treatment is long (at least 12 months after culture conversion according to recommendations by scientific societies) and difficult (at least three drugs are required, each of which have potential adverse events). Moreover, optimal treatment is unknown for the vast majority of NTM and efficacy of treatment is not 100%. That is why, balance between benefit and risk is fundamental. For M. xenopi, the second most common NTM isolated in Europe, treatment is classically based on macrolides or fluoroquinolones, associated with Ethambutol and rifampicin. For M. kansasii, the cornerstone of treatment is rifampicin, which should be associated with two other drugs: Ethambutol Plus Isoniazid or clarithromycin. M. malmoense, which is common in Northern Europe, can be treated by rifampicin, Ethambutol, and clarithromycin and/or fluoroquinolones.

D. Basille - One of the best experts on this subject based on the ideXlab platform.

  • Treatment of Other Nontuberculous Mycobacteria.
    Seminars in Respiratory and Critical Care Medicine, 2018
    Co-Authors: D. Basille, Vincent Jounieaux, Claire Andrejak
    Abstract:

    Nontuberculous mycobacteria (NTM) are numerous, and for the vast majority of them, randomized studies are lacking and data regarding optimal treatment are limited. When Mycobacterium avium complex (MAC) and M. abscessus are excluded, the main NTM are M. xenopi, M. kansasii, M. malmoense, M. szulgai, and M. simiae. Treatment is long (at least 12 months after culture conversion according to recommendations by scientific societies) and difficult (at least three drugs are required, each of which have potential adverse events). Moreover, optimal treatment is unknown for the vast majority of NTM and efficacy of treatment is not 100%. That is why, balance between benefit and risk is fundamental. For M. xenopi, the second most common NTM isolated in Europe, treatment is classically based on macrolides or fluoroquinolones, associated with Ethambutol and rifampicin. For M. kansasii, the cornerstone of treatment is rifampicin, which should be associated with two other drugs: Ethambutol Plus Isoniazid or clarithromycin. M. malmoense, which is common in Northern Europe, can be treated by rifampicin, Ethambutol, and clarithromycin and/or fluoroquinolones.

Vincent Jounieaux - One of the best experts on this subject based on the ideXlab platform.

  • Treatment of Other Nontuberculous Mycobacteria.
    Seminars in Respiratory and Critical Care Medicine, 2018
    Co-Authors: D. Basille, Vincent Jounieaux, Claire Andrejak
    Abstract:

    Nontuberculous mycobacteria (NTM) are numerous, and for the vast majority of them, randomized studies are lacking and data regarding optimal treatment are limited. When Mycobacterium avium complex (MAC) and M. abscessus are excluded, the main NTM are M. xenopi, M. kansasii, M. malmoense, M. szulgai, and M. simiae. Treatment is long (at least 12 months after culture conversion according to recommendations by scientific societies) and difficult (at least three drugs are required, each of which have potential adverse events). Moreover, optimal treatment is unknown for the vast majority of NTM and efficacy of treatment is not 100%. That is why, balance between benefit and risk is fundamental. For M. xenopi, the second most common NTM isolated in Europe, treatment is classically based on macrolides or fluoroquinolones, associated with Ethambutol and rifampicin. For M. kansasii, the cornerstone of treatment is rifampicin, which should be associated with two other drugs: Ethambutol Plus Isoniazid or clarithromycin. M. malmoense, which is common in Northern Europe, can be treated by rifampicin, Ethambutol, and clarithromycin and/or fluoroquinolones.